Regulatory Dendritic Cells for the Prevention and Treatment of Graft-versus-Host Disease.

用于预防和治疗移植物抗宿主病的调节性树突状细胞。

• 批准号: nhmrc : 290214
• 负责人: Prof Geoff Hill
• 金额: $ 11.02万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2004-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/regulatory-dendritic-cells-host-disease/81792
• 关键词: Regulatory; Dendritic; Cells; Prevention; Treatment

Allogeneic bone marrow transplantation (BMT) remains the most effect curative treatment for patients with a number of malignant conditions, especially leukemia. Graft-versus-Host Disease (GVHD) ocurrs when the newly transplanted bone marrow (which includes the immune system) recognises the transplant recipient as foreign and mounts an immune attack against patient tissues. GVHD is the major complication of BMT and is responsible for the death of up to half of the patients who receive this procedure. These studies will focus on the ability of a newly defined type of white blood called a regulatory dendritic cell to prevent this complication and avoid the requirement for BMT patients to take drugs that suppress their immune system.

异基因骨髓移植（BMT）是治疗多种恶性肿瘤，特别是白血病最有效的方法。移植物抗宿主病（GVHD）是指新移植的骨髓（包括免疫系统）将移植受体识别为外来物，并对患者组织进行免疫攻击。移植物抗宿主病是骨髓移植的主要并发症，并导致多达一半接受该手术的患者死亡。这些研究将集中在一种新定义的称为调节性树突状细胞的白色血液类型的能力上，以防止这种并发症，并避免BMT患者需要服用抑制其免疫系统的药物。